KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to 0.49%.

  • Arbutus Biopharma's Return on Capital Employed rose 1400.0% to 0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.62% for FY2024, which is 900.0% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Return on Capital Employed of 0.49% as of Q3 2025, which was up 1400.0% from 0.57% recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Return on Capital Employed high stood at 0.33% for Q2 2022, and its period low was 0.79% during Q1 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.49% (2021), whereas its average is 0.51%.
  • As far as peak fluctuations go, Arbutus Biopharma's Return on Capital Employed skyrocketed by 9300bps in 2021, and later tumbled by -2100bps in 2023.
  • Arbutus Biopharma's Return on Capital Employed (Quarter) stood at 0.42% in 2021, then grew by 7bps to 0.39% in 2022, then tumbled by -54bps to 0.61% in 2023, then decreased by -5bps to 0.63% in 2024, then increased by 22bps to 0.49% in 2025.
  • Its Return on Capital Employed was 0.49% in Q3 2025, compared to 0.57% in Q2 2025 and 0.79% in Q1 2025.